Since registering in 2017, We Give All to combat Hepatitis and Liver Cancer have been actively engaged in community outreach and education. Alongside regular members’ meetings, they mark key global health events such as World Liver Day and World Hepatitis Day, continuing their efforts even during the COVID-19 pandemic through virtual gatherings and Zoom sessions.
In 2024, they were honoured to receive funding from the National Lottery Community Fund, which has significantly enhanced their capacity. This support has enabled them to expand their activities and invite hepatologists to share expert knowledge and provide vital health education to the community.
They provide general education on hepatitis infections and their primary focus is on raising awareness about Hepatitis B through targeted campaigns, advocating for and educating communities on the importance of early Hepatitis B screening and timely treatment as well as empowering communities to spread the word and take action to save lives.
Their activities include regular Zoom meetings and ongoing communication through a WhatsApp group of over 100 stakeholders, who are encouraged to share information widely within their own networks. They distribute educational materials, share updates, and send event invitations via our social media channels.
We Give All to combat Hepatitis and Liver Cancer place special emphasis on World Hepatitis Day. On this day, they bring together doctors, nurses, midwives, and the public to exchange knowledge on hepatitis and liver health. This tradition has been upheld every year since our founding in 2017, including virtual events during the COVID-19 pandemic.
We Give All to combat Hepatitis and Liver Cancer was founded in memory of their founder’s (Zeinab Senessie) father, who passed away in 2015 at King’s College Hospital from liver cancer caused by undiagnosed chronic Hepatitis. He was unaware of his condition until it was too late. Being a chronic hepatitis B patient herself, Zeinab is determined to prevent others from experiencing the same pain and loss. This led her to setting up the organisation; to educate, raise awareness about and raise funds to screen for Hepatitis and support liver health research.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close